New immunosuppressive agents in chronic progressive glomerulopathies: an update

Area of Science:

• Nephrology
• Immunology

Background:

• The exact causes of chronic glomerulopathies remain unclear, but immune system dysfunction is strongly implicated.
• Current treatments often involve corticosteroids alone or in combination with other immunosuppressive agents to manage disease activity and progression.

Purpose of the Study:

• To review the current and emerging roles of immunosuppressive agents in managing chronic glomerulopathies.
• To evaluate the utility of established and novel immunosuppressants, particularly those used in transplantation, for kidney disease treatment.

Main Methods:

• Review of existing literature on immunosuppressant therapies for chronic glomerulopathies.
• Discussion of the application of calcineurin inhibitors (Cyclosporine A, Tacrolimus) and other agents (Mycophenolate mofetil, Sirolimus) in nephrology.

Main Results:

• Cyclosporine A is utilized as a second-line therapy, with its specific indications in lupus nephritis and IgA nephropathy still under investigation.
• Tacrolimus, widely used in transplantation, needs further evaluation for its effectiveness in clinical nephrology.
• Mycophenolate mofetil presents an alternative for patients unresponsive to standard treatments.
• Sirolimus is a recent addition to transplant medicine, with its role in chronic glomerulopathies yet to be determined.

Conclusions:

• Immunosuppressive therapy is a cornerstone in managing chronic glomerulopathies, with ongoing research into newer agents.
• Further clinical trials are essential to define the optimal use of agents like tacrolimus and sirolimus in nephrological practice.